Alpha-antitrypsin (PPL Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAlpha-antitrypsin (PPL Therapeutics)
Drug Alias NameRecombinant AATAAT - PPL TherapeuticsrAAT - PPL TherapeuticsTgAAT - PPL TherapeuticsrecAAT - PPL Therapeutics +[7] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionLeukocyte elastase inhibitorsPeptide hydrolase inhibitorsSerine protease inhibitors
TargetsSerine proteaseLeukocyte elastasePeptide hydrolase
Therapy Area/IndicationsRespiratory Distress Syndrome, AdultCystic Fibrosisalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPpl Therapeutics Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBayer AGPpl Therapeutics Plc
Active IndicationsN/A
Inactive IndicationsRespiratory Distress Syndrome, AdultCystic Fibrosisalpha 1-Antitrypsin Deficiency

Other Information

ATC CodeN/A
Related LinksN/A